Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 151 of 6351
-
Can a Triple-Drug combo tame an aggressive lymphoma without harsh chemo?
Disease control CompletedThe purpose of this study is to evaluate the efficacy and safety of Sintilimab in combination with Pegaspargase and anlotinib in the treatment of stage IV NK/T-cell lymphoma patients unfit for high-dose chemotherapy.
Phase 2 • Sponsor: Rong Tao • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New 9-Valent HPV vaccine aims to shield chinese women from more Cancer-Causing strains
Prevention OngoingThis study will evaluate the efficacy, immunogenicity and safety of 9-valent human papillomavirus (9vHPV; V503) vaccine in Chinese women 20 to 45 years of age. The primary hypotheses are: 9vHPV vaccine reduces the incidence of HPV 31-, 33-, 45-, 52-, and 58-related 12-month persi…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Prevention
Last updated Sep 03, 2026 00:00 UTC
-
New triple therapy aims to stall advanced kidney cancer
Disease control OngoingThis is a multicenter, randomized, double-blinded, controlled Phase 3 trial of cabozantinib in combination with nivolumab and ipilimumab versus nivolumab and ipilimumab in combination with matched placebo. Approximately 840 eligible subjects with intermediate- or poor-risk advanc…
Phase 3 • Sponsor: Exelixis • Aim: Disease control
Last updated Jun 26, 2026 16:06 UTC
-
Can a new eye injection save vision in wet AMD?
Disease control CompletedThis research study will examine the safety and effectiveness of ONS-5010 in participants with AMD. The goal is to prevent vision loss by evaluating the effectiveness of ONS-5010 as compared with ranibizumab.
Phase 3 • Sponsor: Outlook Therapeutics, Inc. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New hope for Hard-to-Treat breast cancer: targeted drug combo in final testing
Disease control OngoingPhase III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metastatic Triple-negative Breast Cancer (TNBC)
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Engineered immune cells take aim at stubborn childhood leukemia
Disease control OngoingThis is a single arm, open-label, multi-center, phase II study to determine the efficacy and safety of tisagenlecleucel in de novo HR pediatric and young adult B-ALL patients who received first-line treatment and are EOC MRD positive. The study will have the following sequential …
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Diabetes drug semaglutide may shield your heart
Disease control CompletedThe researchers are doing this study to look whether the type 2 diabetes medicine, semaglutide, has a positive effect on heart disease. Participants will either get semaglutide tablets or placebo tablets ("dummy" medicine) - which treatment is decided by chance. Participants must…
Phase 3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Can a pill keep blood cancer at bay after a stem cell transplant?
Disease control CompletedThis study will evaluate a new maintenance therapy with the aim of improving the outcome of patients with acute myeloid leukaemia (AML) and myelodysplasia (MDS) after stem cell transplantation.
Phase 3 • Sponsor: University of Birmingham • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Bladder cancer drug combo shows promise in major trial
Disease control CompletedA global study to evaluate peri-operative pembrolizumab with chemotherapy versus placebo to pembrolizumab plus chemotherapy in cisplatin eligible patients.
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
A needle in the neck to shock the heart back to life?
Disease control CompletedThis is an observational, prospective study to verify the feasibility and practicability of percutaneous stellate ganglion block (PSGB) in patient suffering from a refractory out-of-hospital cardiac arrest (OHCA) due to a shockable rhythm and the eventual occurrence of complicati…
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Cholesterol-Lowering drug aims to stop first heart attacks
Disease control CompletedThis study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults without a prior myocardial infarction (MI) or stroke who are at high risk of a cardiovascular event.
Phase 3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo shows promise in High-Risk prostate cancer trial
Disease control OngoingThe purpose of this study is to determine if treatment with apalutamide plus androgen deprivation therapy (ADT) before and after radical prostatectomy (RP) with pelvic lymph node dissection (pLND) in participants with high-risk localized or locally advanced prostate cancer result…
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Can robotic surgery match open surgery in beating cervical cancer?
Disease control Recruiting nowThe purpose of the RACC trial is to compare the oncologic outcome defined as recurrence-free survival (RFS) between robot-assisted and open radical hysterectomy for the treatment of early stage cervical cancer.
Sponsor: Karolinska Institutet • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a cocktail of immune boosters shrink Hard-to-Treat tumors?
Disease control OngoingA study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-927 with ABBV-368, Budigalimab (ABBV-181) and/or chemotherapy in participants with selected solid tumors. This study consists of 2 main parts, a dose-escalation phase and a do…
Phase 1 • Sponsor: AbbVie • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
App alerts heroes: volunteers with defibrillators rush to cardiac arrests
Disease control CompletedThe study will assess 30-day survival for cases where volunteer citizen responders ('heart runners') were activated through a smartphone app to retrieve an AED in case of suspected out-of-hospital cardiac arrest (OHCA) versus standard emergency medical services care. The study wi…
Sponsor: Emergency Medical Services, Capital Region, Denmark • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New pill could offer hope for advanced breast cancer patients
Disease control CompletedThis Phase 3 clinical study compares the efficacy and safety of elacestrant to the standard of care (SoC) options of fulvestrant or an aromatase inhibitor (AI) in women and men with breast cancer whose disease has advanced on at least one endocrine therapy including a CDK4/6 inhi…
Phase 3 • Sponsor: Stemline Therapeutics, Inc. • Aim: Disease control
Last updated Jun 26, 2026 17:03 UTC
-
Breakthrough trial aims to prevent lung damage in tiniest newborns
Prevention OngoingThe purpose of this study is to determine if an investigational drug can prevent Bronchopulmonary Dysplasia, reducing the burden of chronic lung disease in extremely premature infants, as compared to extremely premature infants receiving standard neonatal care alone.
Phase 2 • Sponsor: OHB Neonatology Ltd. • Aim: Prevention
Last updated Aug 05, 2026 00:00 UTC
-
CAR-T therapy takes on standard care in lymphoma battle
Disease control CompletedThis is a randomized, open label, multicenter phase III trial comparing the efficacy, safety, and tolerability of tisagenlecleucel to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline i…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New myeloma cocktail aims to outperform current standard
Disease control OngoingThis is a randomized multicenter study that will compare two treatment regimens (Kyprolis, Revlimid, dexamethasone -KRD vs. Velcade, Revlimid, dexamethasone -VRD) for patients with newly diagnosed multiple myeloma.
Phase 3 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Can an immunotherapy drug revive the fight against resistant lung cancer?
Disease control CompletedThis is a Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study to evaluate the efficacy and safety of Toripalimab injection (JS001) or placebo combined with chemotherapy in Advanced Non-small Cell Lung Cancer (NSCLC) Participants with TKI-resistant EGFR-muta…
Phase 3 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC